Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) belonging to the Medical sector which declined -6.74% and closed its last trading session at $0.62.
The company is expected to report its next EPS on Nov 04 AMC. Currently, the stock has a 1 Year Price Target of $4.08.
The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 3 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Tonix Pharmaceuticals Holding Corp. on 9/30/2016 reported its EPS as $-0.5 with the analysts projecting the EPS of the stock as $-0.55. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 9.1%.
Many analysts have provided their estimated foresights on Tonix Pharmaceuticals Holding Corp. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.34. Whereas they predicted High and Low Earnings Estimate as $-0.3 and $-0.38 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.72.
The Company got Downgrade by ROTH Capital on 7-Sep-16 from Buy to Neutral.
Insider Trades for Tonix Pharmaceuticals Holding Corp. show that the latest trade was made on 12 Sep 2016 where Mario (Ernest B Ph.D.), the Director completed a transaction type “Buy” in which 100000 shares were traded at a price of $0.79.
Over the period of 6 months, Insider Purchases show a total of 15 transaction in which 103594 shares were traded.
3 analysts projected Price Targets for Tonix Pharmaceuticals Holding Corp.. The analysts believe that the company stock price could grow as high as $10. The Low Price target projection by analysts is $1 and the Mean Price Target is $4.08.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has the market capitalization of $16.59 Million. The company rocked its 52-Week High of $7.95 on Jan 5, 2016 and touched its 52-Week Low of $0.6 on Oct 10, 2016. The stock has Return on Assets (ROA) of -118.2 percent. Return on Equity (ROE) stands at -134.1% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -91.98 Percent. The company has Beta Value of 3.08 and ATR value of 0.1. The Weekly and Monthly Volatility stands at 11.35% and 6.79%.
Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.